AbbVie starts Phase I for TRAIL-receptor agonist in cancer

Apogenix AG (Heidelberg, Germany) said partner AbbVie Inc. (NYSE:ABBV) began a Phase I trial to evaluate ABBV-621 (APG880) in 92 patients with relapsed or refractory solid tumors, non-Hodgkin’s lymphoma (NHL) or acute myelogenous leukemia (AML).

The first part of the open-label, international trial will test escalating doses of IV ABBV-621 to identify a maximum tolerated dose (MTD) and/or recommended Phase II dose. The first part will also evaluate pharmacokinetics. The second part will then evaluate objective response rate (ORR)...